Abstract Search

ba0005oc1.1 | Clinical trials and osteoporosis treatment | ECTS2016

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

Saag Kenneth G , Alexandersen Peter , Benhamou Claude-Laurent , Gilchrist Nigel , Halse Johan , Michael Lewiecki E. , Lippuner Kurt , McClung Michael , Shiraki Masataka , DaSilva Carolyn A , Verbruggen Nadia , Scott Boyd B , Lombardi Antonio

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the primary efficacy analysis of the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk compared with placebo in postmenopausal women with osteoporosis. Pre-specified subgroup analyses evaluated the efficacy of ODN in patient subgroups.Women aged ≥65 years, without baseline radiographic...

0 shares

Bone Abstracts

Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)

BiosciAbstracts